Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Apr;20(4):440-9.
doi: 10.1634/theoncologist.2014-0328. Epub 2015 Mar 2.

Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis

Zhiyu Wang  1 , Dan Qiao  1 , Yaohong Lu  1 , Dana Curtis  1 , Xiaoting Wen  1 , Yang Yao  1 , Hui Zhao  2
Affiliations
Comparative Study

Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis

Zhiyu Wang et al. Oncologist. 2015 Apr.

Abstract

Background: Complications from skeletal-related events (SREs) constitute a challenge in the care of cancer patients with bone metastasis (BM).

Objectives: This study evaluated the comparative effectiveness of pamidronate, ibandronate, zoledronate, and denosumab in reducing the morbidity of SREs in cancer patients with BM.

Methods: Medline (1948 to January 2014), Embase (1980 to January 2014), the Cochrane Library (2014 issue 1), and Web of Science with Conference Proceedings (1970 to January 2014) were searched. Only randomized controlled trials assessing denosumab, bisphosphonates, or placebo in cancer patients with BM were included. The primary outcomes were SREs and SREs by type. The network meta-analysis (NMA) was performed with a random-effects Bayesian model.

Results: The NMA included 14 trials with 10,192 patients. Denosumab was superior to placebo in reducing the risk of SREs (odds ratio [OR]: 0.49; 95% confidence interval [CI]: 0.31-0.75), followed by zoledronate (OR: 0.57; 95% CI: 0.41-0.77) and pamidronate (OR: 0.55; 95% CI: 0.41-0.72). Ibandronate compared with placebo could not reduce the risk of SREs. Denosumab was superior to placebo in reducing the risk of pathologic fractures (OR: 0.50; 95% CI: 0.32-0.79), followed by zoledronate (OR: 0.61; 95% CI: 0.43-0.86). Denosumab was superior to placebo in reducing the risk of radiation (OR: 0.51; 95% CI: 0.35-0.75), followed by pamidronate (OR: 0.67; 95% CI: 0.52-0.86) and zoledronate (OR: 0.70; 95% CI: 0.52-0.96).

Conclusion: This NMA showed that denosumab, zoledronate, and pamidronate were generally effective in preventing SREs in cancer patients with BM. Denosumab and zoledronate were also associated with reductions in the risk of pathologic fractures and radiation compared with placebo. Denosumab was shown to be the most effective of the bone-targeted agents.

Keywords: Bisphosphonates; Bone metastasis; Denosumab; Network meta-analysis; Skeletal-related events.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram. Abbreviation: ASCO, American Society of Clinical Oncology.
Figure 2.
Figure 2.
Odds ratios for skeletal-related events (A), pathologic fractures (B), bone radiation (C), bone surgery (D), and spinal cord compression (E) in Bayesian network meta-analysis versus placebo in cancer patients with bone metastases. Abbreviation: CrI, credibility interval.
Figure 3.
Figure 3.
The network meta-analysis rank probabilities for skeletal-related events (SREs) (A), pathologic fractures (B), bone radiation (C), bone surgery (D), and spinal cord compression (E) in cancer patients with bone metastases. The bar chart visualizes the (posterior) probability for each treatment to be best, second-best, and so forth, given the analysis model and the data. Rank of 1 is the worst, indicating the highest incidence of the condition, and rank of 5 is the best, indicating the lowest incidence of the condition.
Figure 4.
Figure 4.
Odds ratios for skeletal-related events (A), pathologic fractures (B), bone radiation (C), bone surgery (D), and spinal cord compression (E) in Bayesian network meta-analysis versus placebo in breast cancer patients with bone metastases. Abbreviation: CrI, credibility interval.
See this image and copyright information in PMC

References

    1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–6249s. - PubMed
    1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl):1588–1594. - PubMed
    1. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082–1090. - PubMed
    1. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006;24:4–12. - PubMed
    1. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–2621. - PubMed